Clicky

Intellia Therapeutics, Inc.(NTLA) News

Date Title
Jun 27 3 Promising Genomics Stocks to Keep an Eye On in 2025
Jun 25 CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
Jun 23 Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Jun 21 Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Jun 18 Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Jun 17 Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Jun 17 Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Jun 15 Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Jun 4 BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Jun 4 How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
Jun 4 Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
May 29 Intellia stock tumbles on safety concerns
May 29 Intellia filing spurs safety concerns over CRISPR drug
Apr 21 Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Apr 9 Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
Feb 24 What's in Store for These 5 Biotech Stocks This Earnings Season?
Feb 24 2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Feb 20 Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
Feb 20 Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
Feb 14 Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently